| Code | CSB-RA623927MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LASN-01, targeting interleukin-11 receptor subunit alpha (IL11RA). IL11RA forms part of the heterodimeric receptor complex for interleukin-11, a member of the IL-6 cytokine family that plays critical roles in hematopoiesis, osteoclast development, and inflammatory responses. The IL-11/IL11RA signaling pathway has been implicated in various pathological conditions, including fibrotic diseases affecting the heart, lung, kidney, and liver, as well as certain cancers where it promotes tumor progression and metastasis. Emerging evidence also links IL-11 signaling to inflammatory bowel disease and metabolic disorders.
LASN-01 represents a therapeutic antibody designed to block IL-11 signaling by preventing ligand binding to IL11RA, thereby inhibiting downstream JAK/STAT activation. This biosimilar antibody provides researchers with a valuable tool for investigating IL-11-mediated pathways in disease models, studying receptor-ligand interactions, and exploring potential therapeutic interventions for fibrosis and cancer. The antibody enables mechanistic studies of IL-11 biology and supports preclinical research into anti-fibrotic and anti-inflammatory strategies.
There are currently no reviews for this product.